<DOC>
	<DOCNO>NCT02921763</DOCNO>
	<brief_summary>This survey intend collect efficacy safety data Duphaston速 Tablets patient endometriosis actual condition use obtain data effectively safely utilizing drug .</brief_summary>
	<brief_title>A Survey Efficacy Safety Patients With Endometriosis</brief_title>
	<detailed_description>In Japan , Duphaston速 Tablets appear 1965 treatment endometriosis use medical institution . However , release danazol early 1980 's gonadotropin-releasing hormone ( GnRH ) agonists late 1980 's , pseudomenopause therapy become mainstream high efficacy . However , pseudopregnancy therapy recognize due adverse reaction associate pseudomenopause therapy . After 2000 , low-dose estrogen/progestin ( LEP ) combination drug ( LEP product , ethinylestradiol/norethisterone combination drug ethinylestradiol/drospirenone combination drug ) dienogest utilized drug safer administer long time . In recent year , Duphaston速 Tablets increase recognize viewpoint efficacy safety drug effect inhibit ovulation effect basal body temperature , diagnosis ovulation condition may make follow basal body temperature , pregnancy may achieve even treatment Duphaston . As previously mention , Duphaston速 Tablets old drug , clinical data Japanese patient ; thus , late clinical efficacy safety data demand mainly obstetrician-gynecologists .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<criteria>Women age 20 &lt; 50 year Subjects chocolate cyst ovary measure 3 cm diameter transvaginal ultrasonography patient enrollment Subjects menstrual cycle 25 38 day ovulate confirm normal menstruation patient enrollment Subjects use GnRH agonist within 6 month patient enrollment Subjects utilized hormone preparation contain corpus luteum hormone estrogen active ingredient , lowdose contraceptive pill , middledose contraceptive pill , testosterone derivative , herbal product indicate endometriosis within 3 month patient enrollment Subjects receive surgical treatment endometriosis transvaginal alcohol fixation , laparotomy laparoscopic surgery within 2 month patient enrollment Subjects pregnant may possibly pregnant patient enrollment Subjects breast feed patient enrollment Subjects determine investigator/subinvestigator suitable subject survey reason Subjects liver disorder liver disease Subjects know hypersensitivity active substance excipients Subjects know suspected progestogen dependent neoplasm ( e.g . meningioma ) Subjects undiagnosed vaginal bleeding Subjects past current history heart kidney disease Subjects porphyria Subjects depression Subjects abnormal liver function value cause acute chronic liver disease Subjects rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>